# KRT-232 and TKI Study in Chronic Myeloid Leukemia

> **NCT04835584** · PHASE1,PHASE2 · RECRUITING · sponsor: **Kartos Therapeutics, Inc.** · enrollment: 109 (estimated)

## Conditions studied

- Chronic Myeloid Leukemia

## Interventions

- **DRUG:** KRT-232
- **DRUG:** Dasatinib
- **DRUG:** Nilotinib

## Key facts

- **NCT ID:** NCT04835584
- **Lead sponsor:** Kartos Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-05-07
- **Primary completion:** 2024-12-31
- **Final completion:** 2026-06-30
- **Target enrollment:** 109 (ESTIMATED)
- **Last updated:** 2022-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04835584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04835584, "KRT-232 and TKI Study in Chronic Myeloid Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04835584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*